Forward Features Calendar

Managers

Alternative Views with DWS Group’s Guido Lombardi

In Alternative Views, Hedgeweek goes behind closed doors with those in the know to get the latest on the hedge fund sector. In our first instalment, we sat down with Guido Lombardi, Head of Research and External Funds Allocation at

Motherson facing hedge fund hurdle in Marelli takeover bid

US distressed debt hedge fund Strategic Value Partners (SVP) is pushing back against Indian auto parts giant Samvardhana Motherson’s proposed $2bn takeover of Marelli, a Japanese car components supplier backed by KKR, according to a report by the Economic Times.

Teton Capital takes activist aim at Atlantic Union Bank

David Sokol’s Teton Capital has launched a launching an activist campaign aimed at shaking up the governance and cost structure at Atlantic Union Bank after quietly building a stake approaching 5% in the $4.4bn regional bank, according to a report

Elliott pressures Sumitomo Realty in rare Japan activist push

Elliott Investment Management has gone public with a rare activist campaign in Japan, urging Sumitomo Realty & Development to significantly improve shareholder returns and overhaul its governance practices – asserting the company is undervalued by at least 40%, according to

Hedge funds eye distressed French PE portfolio companies

A growing number of distressed French private equity portfolio companies – including EQT-owned care home group Colisée and lab operator Cerba – are attracting attention from hedge funds, according to a report by the Financial Times.

Before the mainstream: Re7 Capital’s edge

Evgeny Gokhberg, Founder and Managing Partner at Re7 Capital – winner of both the Liquid Ventures Fund of the Year: Annual Excellence and Sustained Excellence awards at the 2025 Hedgeweek Global Digital Assets Awards – shares how the firm successfully

Activist Parvus builds stake in Novo Nordisk

Activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk, according to a report from the Financial Times, as the Danish pharmaceutical giant faces increasing investor scrutiny over its positioning in the rapidly evolving weight-loss drug market.

Events

08 October, 2026 – 5:00 pm

Directory Listings

Please select one of the below *
Notify Me
Firm Type *
Please select below
Terms & Conditions *
Privacy Policy *